Merck KGaA (XTRA: MRK)
Health Care · Pharmaceuticals · DE
€139.35
+0.69% today · +26.7% 1Y
Merck KGaA (XTRA: MRK) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $70.70B and employs 62,136 people.
Over the last twelve months the share price has gained 26.7%, trading between 100.70 and 148.80.
Tweenvest scores Merck KGaA across four factors: quality 82/100, value 60/100, growth 17/100, dividend 45/100. Its strongest factor is quality.
MRK price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $70.70B
- Revenue (TTM)
- $24.15B
- P/E
- 25.57
- EPS
- 5.45
- Dividend yield
- 1.59%
- Beta (5Y)
- 0.81
- 52-week high
- €148.80
- 52-week low
- €100.70
- Avg volume (3M)
- —
- Shares outstanding
- 434.78M
- Employees
- 62,136
- Next earnings
- —
About Merck KGaA
Merck KGaA is a German science and technology company with operations divided into three core segments: Life Science, Healthcare, and Electronics. The Life Science division supplies essential tools, chemicals, and equipment to academic research institutions, biotechnology firms, pharmaceutical manufacturers, and various industrial sectors. It also offers specialized process development expertise, such as continuous bioprocessing for drug manufacturers, provides a range of testing kits, reagents, and services, and develops solutions for analyzing environmental samples like air, water, and soil. Furthermore, this segment aids in assessing nutritional value and identifying quality control issues. In its Healthcare segment, the company is involved in the entire lifecycle of prescription drugs and biopharmaceuticals, from initial discovery and development through manufacturing and marketing. Its therapeutic focus areas include oncology, neurology and immunology, fertility, endocrinology, cardiovascular diseases, diabetes, thyroid disorders, and multiple sclerosis. This segment also produces general medicines, injection devices, and software for disease monitoring. The Electronics division delivers critical materials for the semiconductor and display industries. It also specializes in surface design, providing delivery systems and services, along with a variety of surface solutions for applications such as cosmetics, effect pigments, and other functional materials. Merck KGaA is also actively engaged in strategic partnerships. These include in-licensing agreements with Debiopharm International SA for developing treatments for head and neck cancer, with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for metastatic colorectal cancer drug candidates, and with Abbisko Therapeutics Co. Ltd. for therapies targeting tenosynovial giant cell tumors. Additionally, the company is involved in collaborations focused on discovering and developing targeted protein degraders against critical oncogenic proteins. Founded in 1668 and headquartered in Darmstadt, Germany, Merck KGaA operates as a subsidiary of E. Merck KG.
- ISIN
- DE0006599905
- Founded
- 1668
- Listed since
- Jun 26, 1998
- Exchange
- XETRA Trading Platform
- Currency
- EUR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,233.66 | -1.06% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $156.45 | +3.84% |
| Roche Holding AGSWX: ROP | $371.62B | CHF373.80 | +0.92% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £124.76 | +3.02% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.57 | +2.15% |
Figures last refreshed Aug 18, 2026.